Author: Caffo Orazio Dipasquale Mariachiara Murgia Viviana Veccia Antonello Galligioni Enzo
Publisher: Informa Healthcare
ISSN: 1742-5255
Source: Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.8, 2013-08, pp. : 1037-1051
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Clinical Pharmacokinetics and Use of Infliximab
By Klotz Ulrich Teml Alexander Schwab Matthias
Clinical Pharmacokinetics, Vol. 46, Iss. 8, 2007-01 ,pp. :
Gemcitabine plus vinorelbine superior in NSCLC
Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. :
ICER favours vinorelbine + cisplatin for NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 534, 2007-01 ,pp. :
Docetaxel: clinical benefit in first-line treatment for NSCLC
Inpharma, Vol. 1, Iss. 1348, 2002-01 ,pp. :